Rapid detection of FLT3-ITD (exon14-15) gene mutations analysis in acute myelogenous leukemia patients by High Resolution Melting analysis
Article Sidebar
Main Article Content
Abstract
Background: Molecular genetic characterization allows prognostic stratification and can potentially alter treatment choices in acute myeloid leukemia (AML). Activating mutations of the Fsm-like tyrosine kinase3 (FLT3) gene, especially FLT3-ITD mutations, have been associated with an adverse prognosis in AML. Therefore, FLT3 mutation detection becomes essential for AML patients. High Resolution Melting (HRM) analysis is an alternative method for the rapid and affordable detection of gene mutations.
Objectives:To establish and evaluate a rapid and affordable method for detecting mutations of FLT3-ITD (exon14-15) gene in acute myeloid leukemia by High Resolution Melting analysis.
Materials and Methods: Thirty-five patients with newly diagnosed AML from Maharaj Nakorn Chiang Mai Hospital were included in this study. FLT3-ITD mutation screening was performed by HRM analysis, and the results were compared with the data obtained using conventional PCR with gel electrophoresis and direct sequencing.
Results: Among the 35 AML patients studied, 6 patients were scored positively for FLT3-ITD mutation in the conventional PCR, whereas HRM analysis identified 7 out of 35 patients who were positive for FLT3-ITD mutation, which was concordant with direct sequencing results. Interestingly, one sample that was positive by HRM analysis was scored by conventional PCR as negative. Therefore, HRM analysis is more sensitive than conventional PCR.
Conclusion: HRM analysis is a rapid and promising screening method for FLT3-ITD mutation, enabling the real-time evaluation of AML progression, which is significant for decision-making regarding treatment. Our results showed that HRM analysis could be a useful clinical tool for the rapid and affordable screening of FLT3-ITD mutation in AML patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016; 2016(1): 348-55. doi: 10.1182/asheducation-2016.1.348.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391-405. doi: 10.1182/blood-2016-03-643544.
Pourrajab F, Zare-Khormizi MR, Hashemi AS, Hekmatimoghaddam S. Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia. Cancer Manag Res. 2020; 12: 2231-53. doi: 10.2147/CMAR.S242479.
Spencer DH, Abel HJ, Lockwood CM, Payton JE, Szankasi P, Kelley TW, et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn. 2013; 15(1): 81-93. doi: 10.1016/j.jmoldx.2012.08.001.
Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003; 5(2): 96-102. doi: 10.1016/S1525-1578(10)60458-8.
Burnatt G, Licínio MA, Gaspar PC, Ferreira AS, Reis ML, Moraes ACRd, et al. Analysis of the presence of FLT3 gene mutation and association with prognostic factors in adult and pediatric acute leukemia patients. Brazilian Journal of Pharmaceutical Sciences. 2017; 53(2). doi: 10.1590/s2175-97902017000216105.
Sakaguchi M, Nakajima N, Yamaguchi H, Najima Y, Shono K, Marumo A, et al. The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia. Leuk Res Rep. 2020; 13: 100198. doi: 10.1016/j.lrr.2020.100198.
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2): 299-312. doi: 10.1038/s41375-018-0357-9.
Vossen RH, Aten E, Roos A, den Dunnen JT. High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum Mutat. 2009; 30(6): 860-6. doi: 10.1002/humu.21019.
Schiwek S, Beule L, Vinas M, Pfordt A, von Tiedemann A, Karlovsky P. High-Resolution Melting (HRM) Curve Assay for the Identification of Eight Fusarium Species Causing Ear Rot in Maize. Pathogens. 2020; 9(4). doi: 10.3390/pathogens9040270.
Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018; 59(10): 2273-86. doi: 10.1080/10428194.2017.1399312.
Shires K, Shankland I, Gerdener T. FLT3 ITD DeTecTIon: A cLoser Look AT The opTIons. Medical technology SA. 2011; 25: 39-46. doi: 10.4102/MTSA.V25I2.37.
Mahmoudi A, Moradabadi A, Noroozi-Aghideh A. Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia. Cancer Treat Res Commun. 2021; 28: 100432. doi: 10.1016/j.ctarc.2021.100432.
Liu Y, Tang J, Wakamatsu P, Xue H, Chen J, Gaynon PS, et al. High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. Front Pediatr. 2014; 2: 96. doi: 10.3389/fped.2014.00096.
Montgomery JL, Sanford LN, Wittwer CT. High-resolution DNA melting analysis in clinical research and diagnostics. Expert Rev Mol Diagn. 2010; 10(2): 219-40. doi: 10.1586/erm.09.84.
Erali M, Voelkerding KV, Wittwer CT. High resolution melting applications for clinical laboratory medicine. Exp Mol Pathol. 2008; 85(1): 50-8. doi: 10.1016/j.yexmp.2008.03.012.
Taylor Claire F. Mutation scanning using high-resolution melting. Biochemical Society Transactions. 2009; 37(2): 433-7. doi: 10.1042/BST0370433.
Jiang M, Li J, Zhou J, Xing C, Xu JJ, Guo F. High-resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia. Oncol Lett. 2019; 18(1): 814-21. doi: 10.3892/ol.2019.10342.